FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Schwartz

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Procedures

Anatomy

Co-author Network

Publications

TOP 3
Sujatha Iyengar; David H Schwartz
Acquisition of CD4-dependence by CD4-independent SIV passaged in human peripheral blood mononuclear cells.
Sujatha Iyengar; David H Schwartz
Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.
Takahiro Okazaki; C David Pendleton; Pablo Sarobe; Elaine K Thomas; Sujatha Iyengar; Clayton D Harro; David H Schwartz; Jay A Berzofsky
Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Schwartz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sujatha Iyengar; David H Schwartz
Acquisition of CD4-dependence by CD4-independent SIV passaged in human peripheral blood mononuclear cells.
Retrovirology 2012;9():61.
2011: Sujatha Iyengar; David H Schwartz
Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.
AIDS research and human retroviruses 2011;27(5):519-23.
2006: Takahiro Okazaki; C David Pendleton; Pablo Sarobe; Elaine K Thomas; Sujatha Iyengar; Clayton D Harro; David H Schwartz; Jay A Berzofsky
Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(6):3753-9.
2005: David H Schwartz; Sujatha Iyengar
Toward genetic rationalization of antiretroviral therapy for HIV.
AIDS (London, England) 2005;19(9):975-7.
2004: Sujatha Lyengar; David H Schwartz
How do cell-free HIV virions avoid infecting dead-end host cells and cell fragments?
AIDS reviews 2004;6(3):155-60.
2004: Rohan John; Silvio Arango-Jaramillo; Steve Self; David H Schwartz
Modeling partially effective HIV vaccines in vitro.
The Journal of infectious diseases 2004;189(4):616-23.
2004: Rohan John; Silvio Arango-Jaramillo; Gnanadurai J Finny; David H Schwartz
Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5.
Journal of acquired immune deficiency syndromes (1999) 2004;35(1):1-8.
2003: Sujatha Iyengar; Bennett Chin; Joseph B Margolick; Beulah P Sabundayo; David H Schwartz
Anatomical loci of HIV-associated immune activation and association with viraemia.
Lancet 2003;362(9388):945-50.
2003: Rajesh Kannangai; Ramachandran V Shaji; Sandeep Ramalingam; Mary V Jesudason; Oriapadickal C Abraham; Renu George; Arvindh Shanmugam; David H Schwartz; Gopalan Sridharan
HIV-2 subtype circulating in India (south).
Journal of acquired immune deficiency syndromes (1999) 2003;33(2):219-22.
2002: Kalpana Gupta; Michael G Hudgens; Lawrence Corey; M Juliana McElrath; Kent J Weinhold; David C Montefiori; Geoffrey J Gorse; Sharon E Frey; Michael C Keefer; Thomas G Evans; Raphael Dolin; David H Schwartz; Clayton D Harro; Barney Graham; Paul Spearman; Mark MULLIGAN; Paul A Goepfert
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):254-61.
2001: Rajesh Kannangai; Sandeep Ramalingam; Kotha Jaya Prakash; Oriapadickal C Abraham; Renu George; Renan C Castillo; David H Schwartz; Mary V Jesudason; Gopalan Sridharan
A peptide enzyme linked immunosorbent assay (ELISA) for the detection of human immunodeficiency virus type-2 (HIV-2) antibodies: an evaluation on polymerase chain reaction (PCR) confirmed samples.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2001;22(1):41-6.
2001: Thomas G Evans; Esper Kallas; M Campbell; J Andrews; David H Schwartz; Michael C Keefer; P Caudrelier
Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production.
Immunology letters 2001;77(1):7-15.
2001: John S Lambert; Michael C Keefer; Mark MULLIGAN; David H Schwartz; Jiri Mestecky; Kent J Weinhold; C Smith; RH Hsieh; Zina Moldoveanu; Patricia Fast; B Forrest; W Koff
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
Vaccine 2001;19(23-24):3033-42.
2001: Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2000: R Bures; Alicia Gaitan; T Zhu; C Graziosi; Kevin M McGrath; Jim Tartaglia; P Caudrelier; Raphaelle El Habib; M Klein; Adriano Lazzarin; Donald Stablein; Mark Deers; Lawrence Corey; ML Greenberg; David H Schwartz; David C Montefiori
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
AIDS research and human retroviruses 2000;16(18):2019-35.
2000: Rajesh Kannangai; Sandeep Ramalingam; Kotha Jaya Prakash; Oriapadickal C Abraham; Renu George; Renan C Castillo; David H Schwartz; Mary V Jesudason; Gopalan Sridharan
Molecular confirmation of human immunodeficiency virus (HIV) type 2 in HIV-seropositive subjects in south India.
Clinical and diagnostic laboratory immunology 2000;7(6):987-9.
2000: S Iyengar; David H Schwartz; Janice E Clements; James E K Hildreth
CD4-independent, CCR5-dependent simian immunodeficiency virus infection and chemotaxis of human cells.
Journal of virology 2000;74(15):6720-4.
2000: Renan C Castillo; Silvio Arango-Jaramillo; Rohan John; B C Turner; E Zimmerman; David H Schwartz
Rapid communication: development of in vitro resistance to macrophage-tropic- and T-cell-line-adapted HIV-1 strains among HIV-positive volunteers treated with highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;24(3):197-202.
2000: M Juliana McElrath; Lawrence Corey; David Montefiori; Mark Wolff; David H Schwartz; Michael C Keefer; Robert B Belshe; Barney S Graham; T Matthews; P Wright; Geoffrey J Gorse; Raphael Dolin; Phillip W. Berman; D Francis; AM Duliege; Dani P Bolognesi; Donald Stablein; N Ketter; Patricia Fast
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 2000;16(9):907-19.
2000: EG Kokkotou; Jean-louis Sankale; Indu Mani; Aissatou Gueye-Ndiaye; David H Schwartz; Myron E Essex; Souleymane MBoup; Phyllis J Kanki
In vitro correlates of HIV-2-mediated HIV-1 protection.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(12):6797-802.
2000: Stephen A Migueles; M Shirin Sabbaghian; W Lesley Shupert; Maria Bettinotti; Francesco M Marincola; L Martino; Claire W Hallahan; Sara M Selig; David H Schwartz; J Sullivan; Mark Connors
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(6):2709-14.
2000: Renan C Castillo; Silvio Arango-Jaramillo; Rohan John; Kent J Weinhold; P Kanki; Lucy Minnich Carruth; David H Schwartz
Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.
The Journal of infectious diseases 2000;181(3):897-903.
2000: P Srikanth; Renan C Castillo; Gopalan Sridharan; T Jacob John; Anand Zachariah; Dilip Mathai; David H Schwartz
Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India.
International journal of STD & AIDS 2000;11(1):49-51.
1999: Charles L Bennett; David H Schwartz; D R Lane; AM Sipler; M Bhattacharya; M Kozloff; Daniel W Berland; D Pitrak; A Moswin; R Luskin-Hawk; Robert A Weinstein
Variations in inpatient care for HIV-related tuberculosis patients during a recent nosocomial outbreak of multidrug-resistant tuberculosis.
Journal of acquired immune deficiency syndromes (1999) 1999;21(4):348-9.
1999: S Iyengar; David H Schwartz; James E K Hildreth
T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(10):6263-7.
1999: Rajesh Kannangai; Sandeep Ramalingam; Renan C Castillo; Palla-George Babu; T Jacob John; Gopalan Sridharan; David H Schwartz
HIV-2 status in southern India.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1999;93(1):30-1.
1998: UK Sharma; J Trujillo; Haifeng Song; F P Saitta; Oliver Laeyendecker; Renan C Castillo; Silvio Arango-Jaramillo; Gopalan Sridharan; Markus Dettenhofer; Karin J Blakemore; XIAOFANG YU; David H Schwartz
A novel factor produced by placental cells with activity against HIV-1.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6406-12.
1998: Donald P Francis; TJ Gregory; M Juliana McElrath; Robert B Belshe; Geoffrey J Gorse; Sricharoen Migasena; Dwip Kitayaporn; P Pitisuttitham; T Matthews; David H Schwartz; Phillip W. Berman
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS research and human retroviruses 1998;14 Suppl 3():S325-31.
1998: S Iyengar; James E K Hildreth; David H Schwartz
Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells.
Journal of virology 1998;72(6):5251-5.
1998: B R Davis; F P Saitta; Gerhard Bauer; B A Bunnell; R A Morgan; David H Schwartz
Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages.
Human gene therapy 1998;9(8):1197-207.
1998: Mary Lou Clements-Mann; Kent J Weinhold; TJ Matthews; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; RH Hsieh; Jiri Mestecky; Susan Zolla-Pazner; J Mascola; David H Schwartz; Robert Siliciano; Lawrence Corey; Peter F Wright; Robert B Belshe; Raphael Dolin; S Jackson; S Xu; Patricia Fast; MC Walker; Donald Stablein; Jean-Louis Excler; Jim Tartaglia; E Paoletti
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1998: Giuseppe Pantaleo; OJ Cohen; T Schacker; M Vaccarezza; C Graziosi; G Paolo Rizzardi; J Kahn; CH Fox; S M Schnittman; David H Schwartz; Lawrence Corey; Anthony Fauci
Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy.
Nature medicine 1998;4(3):341-5.
1998: Barney S Graham; M Juliana McElrath; Ruth I Connor; David H Schwartz; Geoffrey J Gorse; Michael C Keefer; Mark MULLIGAN; TJ Matthews; Steven Wolinsky; David C Montefiori; Sten Vermund; John S Lambert; Lawrence Corey; Robert B Belshe; Raphael Dolin; Peter F Wright; Bette T Korber; M C Wolff; Patricia Fast
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
The Journal of infectious diseases 1998;177(2):310-9.
1998: Lawrence Corey; M Juliana McElrath; Kent J Weinhold; T Matthews; Donald Stablein; B Graham; Michael C Keefer; David H Schwartz; Geoffrey J Gorse
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(2):301-9.
1997: David H Schwartz; Renan C Castillo; Silvio Arango-Jaramillo; UK Sharma; Haifeng Song; Gopalan Sridharan
Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons.
The Journal of infectious diseases 1997;176(5):1168-74.
1997: Michael C Keefer; Mark Wolff; Geoffrey J Gorse; Barney S Graham; Lawrence Corey; Mary Lou Clements-Mann; N Verani-Ketter; S Erb; C M Smith; Robert B Belshe; LJ Wagner; M Juliana McElrath; David H Schwartz; Patricia Fast
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1997;13(14):1163-77.
1997: Phillip W. Berman; A M Gray; T Wrin; JC Vennari; D J Eastman; G R Nakamura; D P Francis; Geoffrey J Gorse; David H Schwartz
Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
The Journal of infectious diseases 1997;176(2):384-97.
1997: David H Schwartz; Oliver Laeyendecker; Silvio Arango-Jaramillo; Renan C Castillo; M J Reynolds
Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.
Lancet 1997;350(9073):256-9.
1997: John S Lambert; Raphael P Viscidi; M C Walker; Barbara Clayman; M Winget; Mark Wolff; David H Schwartz
Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1997;4(3):302-8.
1997: UK Sharma; Haifeng Song; FF Willingham; J Hannig; Charles Flexner; Homayoon Farzadegan; C Nicolau; David H Schwartz
Diagnosis of human immunodeficiency virus infection using citrated whole blood.
Clinical and diagnostic laboratory immunology 1997;4(3):261-3.
1997: SH Pincus; K G Messer; R Cole; R Ireland; T C VanCott; A Pinter; David H Schwartz; B S Graham; Geoffrey J Gorse
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(7):3511-20.
1997: Alexander R Irvine; L Lonn; David H Schwartz; Marco A Zarbin; F Ballesteros; Stewart Kroll
Retinal detachment in AIDS: long-term results after repair with silicone oil.
The British journal of ophthalmology 1997;81(3):180-3.
1997: Ping Chen; Gerhard Bauer; J Mitchell; R Factor; Richard B Markham; David H Schwartz
N-acetyl-cysteine and L-2-oxothiazolidine-4-carboxylic acid enhance contact-dependent growth of HIV in resting peripheral blood mononuclear cells (PBMC) in vitro and increase recovery of HIV from human-PBMC SCID mice.
AIDS (London, England) 1997;11(1):33-41.
1997: UK Sharma; Haifeng Song; S J Casella; David H Schwartz
Failure of insulin-like growth factor type I to suppress HIV type 1 in adult or umbilical cord mononuclear blood cells.
AIDS research and human retroviruses 1997;13(1):105-10.
1996: Richard B Markham; David H Schwartz; A Templeton; Joseph B Margolick; Homayoon Farzadegan; David Vlahov; XIAOFANG YU
Selective transmission of human immunodeficiency virus type 1 variants to SCID mice reconstituted with human peripheral blood monoclonal cells.
Journal of virology 1996;70(10):6947-54.
1996: I Stefanová; MW Saville; C Peters; Farley R Cleghorn; David H Schwartz; D J Venzon; K J Weinhold; Noreen Jack; Courtenay Bartholomew; William A Blattner; Robert Yarchoan; J B Bolen; ID Horak
HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.
The Journal of clinical investigation 1996;98(6):1290-7.
1996: Barney S Graham; Michael C Keefer; M Juliana McElrath; Geoffrey J Gorse; David H Schwartz; Kent J Weinhold; TJ Matthews; J R Esterlitz; F Sinangil; Patricia Fast
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
Annals of internal medicine 1996;125(4):270-9.
1996: David H Schwartz; Raphael P Viscidi; Oliver Laeyendecker; Haifeng Song; Stuart C Ray; N Michael
Predominance of defective proviral sequences in an HIV + long-term non-progressor.
Immunology letters 1996;51(1-2):3-6.
1996: P F Tosi; David H Schwartz; U Sharma; Y Mouneimne; J Hannig; G Li; G McKinley; M Grieco; Charles Flexner; J Lazarte; D Norse; C Nicolau; David J Volsky
Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1.
Blood 1996;87(11):4839-44.
1996: John R Mascola; Stuart Snyder; O S Weislow; S M Belay; Robert B Belshe; David H Schwartz; M L Clements; Raphael Dolin; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; MC Walker; K F Wagner; John G McNeil; Francine E McCutchan; Donald S. Burke
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):340-8.
1995: David H Schwartz
Early treatment of HIV infection.
The New England journal of medicine 1995;333(26):1782; author reply 1783.
1995: T W Chun; Diana Finzi; Joseph B Margolick; Karen Chadwick; David H Schwartz; Robert Siliciano
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.
Nature medicine 1995;1(12):1284-90.
1995: Dominique Salmon-Ceron; A Fontbonne; J Saba; T May; F Raffi; C Chidiac; O Patey; Jean-Pierre Aboulker; David H Schwartz; Jean-Louis Vildé
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
The Journal of infectious diseases 1995;172(3):656-64.
1995: Miguel-Angel Perales; David H Schwartz; J A Fabry; Judy Lieberman
A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(1):27-35.
1995: Nelson L Michael; G Chang; L A d'Arcy; Philip K Ehrenberg; R Mariani; M P Busch; Deborah L Birx; David H Schwartz
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus.
Journal of virology 1995;69(7):4228-36.
1995: David H Schwartz; A Mazumdar; S Winston; S Harkonen
Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines.
Clinical and diagnostic laboratory immunology 1995;2(3):268-71.
1995: P S Sarin; C A Mora; PH Naylor; Richard B Markham; David H Schwartz; J Kahn; P Heseltine; B Gazzard; M Youle; A Rios
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(3):401-7.
1995: David H Schwartz; UK Sharma; Elizabeth J. Perlman; Karin J Blakemore
Adherence of human immunodeficiency virus-infected lymphocytes to fetal placental cells: a model of maternal --> fetal transmission.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(4):978-82.
1994: Michael C Keefer; Barney S Graham; Robert B Belshe; David H Schwartz; Lawrence Corey; Dani P Bolognesi; Donald Stablein; D C Montefiori; M Juliana McElrath; M L Clements
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1994;10(12):1713-23.
1994: David H Schwartz; U Sharma; M Busch; Kent J Weinhold; T Matthews; J Lieberman; D Birx; H Farzedagen; Joseph B Margolick; Thomas C Quinn
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor.
AIDS research and human retroviruses 1994;10(12):1703-11.
1994: Geoffrey J Gorse; David H Schwartz; B S Graham; TJ Matthews; D M Stablein; Sharon E Frey; Robert B Belshe; M L Clements; P F Wright; M Eibl
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Clinical and experimental immunology 1994;98(2):178-84.
1994: Barney S Graham; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; M Juliana McElrath; TJ Matthews; Peter F Wright; Robert B Belshe; M L Clements; Raphael Dolin
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1994;170(4):782-6.
1994: David H Schwartz; L M Cosentino; A Shirai; Jacqueline Conover; S Daniel; Dennis M Klinman
Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein.
Journal of acquired immune deficiency syndromes 1994;7(5):447-53.
1994: Phillip W. Berman; D J Eastman; D M Wilkes; G R Nakamura; T J Gregory; David H Schwartz; Geoffrey J Gorse; R Belshe; M L Clements; R A Byrn
Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
AIDS (London, England) 1994;8(5):591-601.
1994: David H Schwartz
Potential pitfalls on the road to an effective HIV vaccine.
Immunology today 1994;15(2):54-7.
1993: Robert B Belshe; M L Clements; Raphael Dolin; Barney S Graham; J McElrath; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; P Wright; L Corey
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
The Journal of infectious diseases 1993;168(6):1387-95.
1993: D C Montefiori; Barney S Graham; J Zhou; J Zhou; R A Bucco; David H Schwartz; Lisa A Cavacini; Marshall R Posner
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
The Journal of clinical investigation 1993;92(2):840-7.
1993: David H Schwartz; Geoffrey J Gorse; M L Clements; Robert B Belshe; Allen E Izu; AM Duliege; P Berman; T Twaddell; Donald Stablein; R Sposto
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
Lancet 1993;342(8863):69-73.
1993: S H Pincus; K G Messer; David H Schwartz; George K Lewis; B S Graham; William A Blattner; G Fisher
Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
The Journal of clinical investigation 1993;91(5):1987-96.
1993: Barney S Graham; TJ Matthews; Robert B Belshe; M L Clements; Raphael Dolin; Peter F Wright; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; Dani P Bolognesi
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1993;167(3):533-7.
1993: R Wood; J G Montoya; S K Kundu; David H Schwartz; Thomas C Merigan
Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
The Journal of infectious diseases 1993;167(3):519-25.
1992: Scott A Hammond; Robert Bollinger; P E Stanhope; Thomas C Quinn; David H Schwartz; M L Clements; Robert Siliciano
Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
The Journal of experimental medicine 1992;176(6):1531-42.
1992: Kent J Weinhold; Jim Tartaglia; E Paoletti; B Graham; David H Schwartz; J McElrath; N Roberts; Geoffrey J Gorse
Specific activation strategies for amplification of low CTL signals.
AIDS research and human retroviruses 1992;8(8):1373.
1992: A G Clark; Mark Holodniy; David H Schwartz; David A Katzenstein; Thomas C Merigan
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.
Journal of acquired immune deficiency syndromes 1992;5(1):52-9.
1991: mark steinhoff; B S Auerbach; Kenrad E Nelson; David Vlahov; R L Becker; Neil M H Graham; David H Schwartz; A H Lucas; Richard E Chaisson
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection.
The New England journal of medicine 1991;325(26):1837-42.
1991: Mark Holodniy; David A Katzenstein; S Sengupta; A M Wang; C Casipit; David H Schwartz; M Konrad; E Groves; Thomas C Merigan
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction.
The Journal of infectious diseases 1991;163(4):862-6.
1991: B R Davis; David H Schwartz; J C Marx; C E Johnson; J M Berry; J Lyding; T C Merigan; A Zander
Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo.
Journal of virology 1991;65(4):1985-90.
1991: David H Schwartz; G Skowron; Thomas C Merigan
Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.
Journal of acquired immune deficiency syndromes 1991;4(1):11-23.
1990: D Portnoi; A M Stall; David H Schwartz; Thomas C Merigan; Leonore A Herzenberg; T Basham
Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(5):1705-10.
1990: David H Schwartz; T C Merigan
Interleukin-2 in the treatment of HIV disease.
Biotherapy (Dordrecht, Netherlands) 1990;2(2):119-36.
1987: T A Chatila; David H Schwartz; Richard A Miller; R S Geha
Requirement for mitogen, T cell-accessory cell contact, and interleukin 1 in the induction of resting T-cell proliferation.
Clinical immunology and immunopathology 1987;44(2):235-47.
1984: David H Schwartz; J L Hurwitz; N S Greenspan; Peter C Doherty
Priming of virus-immune memory T cells in newborn mice.
Infection and immunity 1984;43(1):202-5.
1984: David H Schwartz; Peter C Doherty
Induction of early alloantigen tolerance in thymus and spleen.
Thymus 1984;6(1-2):105-20.
1982: David H Schwartz; Peter C Doherty
Induction of neonatal tolerance to H-2k in B6 mice does not allow the emergence of T cells specific for H-2k plus vaccinia virus.
The Journal of experimental medicine 1982;156(3):810-21.
1981: Peter C Doherty; David H Schwartz; J R Bennink; R Korngold
Factors influencing the vaccinia-specific cytotoxic response of thymocytes from normal and chimeric mice.
Transplantation proceedings 1981;13(4):1850-3.
1981: David H Schwartz; Peter C Doherty
Virus-immune and alloreactive response characteristics of thymocytes and spleen cells from young mice.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(4):1411-4.
1981: J R Bennink; David H Schwartz; Peter C Doherty
Negative selection experiments support the idea that T-T help is required for the H-Y specific cytotoxic T cell response.
Cellular immunology 1981;60(2):347-53.
1981: Peter C Doherty; R Korngold; David H Schwartz; J R Bennink
Development and loss of virus-specific thymic competence in bone marrow radiation chimeras and normal mice.
Immunological reviews 1981;58():37-72.